Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: UZEDY
Published 2026-03-18 · Last reviewed 2026-03-25 · 6 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Uzedy is a long-acting subcutaneous risperidone formulation used for maintenance treatment of schizophrenia and bipolar I disorder with monthly or every-2-month dosing options.
Pharmacology mirrors risperidone/paliperidone-class D2/5-HT2A blockade: prolactin elevation and EPS can be limiting, and metabolic monitoring remains important.
Label describes a subcutaneous depot with two absorption peaks and steady state approached within ~2 months of initiation. The mean apparent half-life is ~14–22 days, reflecting prolonged release and absorption.
For depot comparisons and planning across antipsychotics, see the LAI Navigator and the compare tool.
Uzedy is often selected when a less frequent visit cadence (monthly or every 2 months) is desired and the clinic can reliably deliver on the scheduled injection plan. Practical constraints include injection-site reactions, prolactin/EPS monitoring, and slower dose "steerability" compared with oral therapy.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Risperidone antagonizes dopamine D2 and serotonin 5-HT2A receptors with additional activity at α1-adrenergic and histamine H1 receptors.
D2 blockade supports antipsychotic effects but contributes to prolactin elevation and EPS risk, especially at higher doses.